Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Carlos Fernández-del Castillo

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111915471. Sources: OpenAlex.

Their work

Papers
35 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
191
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 4 papers · 2021: 4 papers · 2022: 6 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 5 papers

Papers 35

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1001/jamasurg.2026.3716↗
  2. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  3. Disparities in the diagnosis and management of exocrine pancreatic insufficiency in resectable vs metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag084↗
  4. Lymph Node Yield Is Associated With Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoa… Co-author DOI 10.1097/sla.0000000000006432↗
  5. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000007214↗
  6. Preoperative Biopsy Is Not Associated With Adverse Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Upfront Resection. Co-author DOI 10.1016/j.jss.2025.01.007↗
  7. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  8. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  9. Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
  10. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  11. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  12. Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. First author DOI 10.1007/s00535-022-01915-2↗
  13. Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. First author DOI 10.1007/s00535-022-01922-3↗
  14. A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.1053/j.gastro.2022.07.005↗
  15. Helping Patients Understand Pancreatic Cancer Using Animated Pancreas Patient Education With Visual Formats of Learning. Co-author DOI 10.1097/mpa.0000000000002087↗
  16. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Last author DOI 10.1097/sla.0000000000004143↗
  17. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cance… Co-author DOI 10.3390/cancers14040868↗
  18. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Last author DOI 10.1002/bjs.12003↗
  19. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  20. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.07.025↗
  21. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  22. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Co-author DOI 10.1016/j.pan.2020.03.011↗
  23. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  24. Primary and Metastatic Pancreatic Cancer Cells Exhibit Differential Migratory Potentials. Co-author DOI 10.1097/mpa.0000000000001459↗
  25. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001590↗
  26. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  27. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  28. Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. Co-author DOI 10.1097/sla.0000000000002633↗
  29. Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2018.0979↗
  30. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarc… Co-author DOI 10.1097/sla.0000000000001763↗
  31. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM. Co-author DOI 10.1097/sla.0000000000001837↗
  32. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-0256↗
  33. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2013.10.027↗
  34. Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle. Co-author DOI 10.1593/tlo.13400↗
  35. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Co-author DOI 10.1634/theoncologist.2012-0435↗

Closest collaborators

The 25 strongest of 191 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith D. Lillemoe · 24 shared papers, 2013–2026 · strength 3.17
  2. Motaz Qadan · 16 shared papers, 2019–2026 · strength 2.60
  3. Cristina Rosa Ferrone · 18 shared papers, 2013–2026 · strength 1.99
  4. Theodore Sunki Hong · 15 shared papers, 2013–2026 · strength 1.74
  5. Colin D. Weekes · 9 shared papers, 2019–2026 · strength 1.38
  6. Jennifer Yon-Li Wo · 11 shared papers, 2013–2026 · strength 1.36
  7. David P. Ryan · 12 shared papers, 2013–2026 · strength 1.25
  8. Andrew Louis Warshaw · 9 shared papers, 2020–2024 · strength 1.15
  9. Andrew Scott Liss · 6 shared papers, 2019–2022 · strength 0.97
  10. Giulio Belfiori · 4 shared papers, 2023–2026 · strength 0.77
  11. Massimo Falconi · 4 shared papers, 2023–2026 · strength 0.77
  12. Stefano Crippa · 4 shared papers, 2023–2026 · strength 0.77
  13. David Tsai Ting · 6 shared papers, 2019–2026 · strength 0.75
  14. Lawrence Scott Blaszkowsky · 7 shared papers, 2013–2026 · strength 0.71
  15. Louisa Bolm · 3 shared papers, 2022–2026 · strength 0.69
  16. Zhi Ven Fong · 3 shared papers, 2019–2026 · strength 0.64
  17. Gabriella Lionetto · 3 shared papers, 2023–2026 · strength 0.63
  18. Maximiliano Servín-Rojas · 2 shared papers, 2025–2026 · strength 0.57
  19. Kazumichi Kawakubo · 2 shared papers, 2022 · strength 0.52
  20. Thomas P. Hank · 4 shared papers, 2020–2024 · strength 0.52
  21. Jon Michael Harrison · 3 shared papers, 2022–2026 · strength 0.43
  22. Stefano Partelli · 2 shared papers, 2026 · strength 0.42
  23. Federico De Stefano · 2 shared papers, 2026 · strength 0.42
  24. Domenico Tamburrino · 2 shared papers, 2026 · strength 0.42
  25. Marco Schiavo Lena · 2 shared papers, 2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.